Oppenheimer Downgrades DigitalOcean Holdings to Perform, Announces $40 Price Target
Oppenheimer analyst Timothy Horan downgrades DigitalOcean Holdings (NYSE:DOCN) from Outperform to Perform and announces $40 price target.
Check Out 3 High-Yielding Dividend Stocks In Utilities Sector From Wall Street’s Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Exane BNP Paribas Upgrades Alphabet to Outperform, Announces $123 Price Target
Exane BNP Paribas analyst Stefan Slowinski upgrades Alphabet (NASDAQ:GOOGL) from Neutral to Outperform and announces $123 price target.
Barclays Maintains Equal-Weight on G-III Apparel Group, Raises Price Target to $15
Barclays analyst Paul Kearney maintains G-III Apparel Group (NASDAQ:GIII) with a Equal-Weight and raises the price target from $13 to $15.
Tigress Financial Reiterates Buy on Cisco Systems, Maintains $73 Price Target
Tigress Financial analyst Ivan Feinseth reiterates Cisco Systems (NASDAQ:CSCO) with a Buy and maintains $73 price target.
Elon Musk Reacts As Bill Ackman Flags First Republic’s Risk Spreading To Largest Banks: ‘…Astounding’
The banking crisis continues to play out, with skeletons continuing to tumble out of the closet.
XPeng Likely To Report Wider Q4 Loss, Here’s A Look At Recent Price Target Changes By Analysts
XPeng Inc. (NYSE: XPEV) is expected to report its fourth quarter and fiscal year 2022 unaudited financial results before the opening bell on March 17, 2023.
PagerDuty Showed Non-GAAP Profitability Ahead Of Plan, Robust Guidance Despite Difficult Environment: Analyst
RBC Capital analyst Matthew Hedberg maintains PagerDuty Inc (NYSE:PD) with an Outperform and raises the price target from $32 to $34. Amidst…
Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $55
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $65 to $55.
Barclays Maintains Underweight on LivePerson, Lowers Price Target to $4
Barclays analyst Ryan Macwilliams maintains LivePerson (NASDAQ:LPSN) with a Underweight and lowers the price target from $11 to $4.